Molecular Partners AG (MOLN) community

MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30

$3.01−0.08 (-2.59%)

Close on Nov 12, 2026Market cap $121.53MP/E –Yield –

Community

Notes and questions about Molecular Partners from other investors

No posts about MOLN yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Molecular Partners's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MOLN.

Compare: MOLN vs CRIS · MOLN vs TCRX · MOLN vs IPHA · MOLN vs RLAY · MOLN vs ELOX

Revenue growth-100.0% · median -38.4%

Company	Revenue	Growth
RLAY	$10.35M	+23.9%
TCRX	$5.19M	-38.4%
CRIS	$4.31M	-62.2%
MOLN	CHF 0	-100.0%
IPHA	–	–
ELOX	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 34
Held by institutions: 8.9%
Auditor: KPMG AG
SEC CIK: 1745114

Advertisement
300 × 250

See a number that looks wrong?